Freiburg, Germany
Resuscitec, headquartered in Germany, is a pioneering medical device company founded in 2010 as a spin-off from the University Hospital Freiburg. Operating within the Biotechnology and Health Care sectors, its mission is clear: advancing emergency and intensive care medicine globally. The company focuses on extracorporeal cardiopulmonary resuscitation (ECPR), providing innovative solutions for situations where traditional resuscitation methods prove insufficient.
Their standout offering, the CARL technology, is designed for comprehensive, patient-specific body reperfusion, potentially revolutionizing emergency care. An integral part of their strategy involves training emergency teams through their CARL Academy, ensuring proficient application of their unique therapy.
With significant early support, including a €1.57M grant from Horizon 2020 FTI in June 2016, Resuscitec stands poised for scaling. For investors, the company represents a cutting-edge opportunity in the vital intersection of technology and medical care.
